These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24875783)

  • 41. A two-stage algorithm for designing phase I cancer clinical trials for two new molecular entities.
    Su Z
    Contemp Clin Trials; 2010 Jan; 31(1):105-7. PubMed ID: 19879974
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
    Du Y; Yin J; Sargent DJ; Mandrekar SJ
    J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Three-dose-cohort designs in cancer phase I trials.
    Huang B; Chappell R
    Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Surv-CRM-12: A Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression.
    Andrillon A; Chevret S; Lee SM; Biard L
    Stat Med; 2022 Dec; 41(29):5753-5766. PubMed ID: 36259523
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Practical modifications of the continual reassessment method for phase I cancer clinical trials.
    Faries D
    J Biopharm Stat; 1994 Jul; 4(2):147-64. PubMed ID: 7951271
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A simple technique to evaluate model sensitivity in the continual reassessment method.
    Cheung YK; Chappell R
    Biometrics; 2002 Sep; 58(3):671-4. PubMed ID: 12230003
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Performance of two-stage continual reassessment method relative to an optimal benchmark.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2013; 10(6):862-75. PubMed ID: 24085776
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Extended model-based designs for more complex dose-finding studies.
    O'Quigley J; Conaway M
    Stat Med; 2011 Jul; 30(17):2062-9. PubMed ID: 21351287
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dose-finding design for multi-drug combinations.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Bayesian three-parameter logistic model for early- and late-onset DLTs in oncology Phase I studies.
    Zheng W; Zhao Y; Lu Y; Miao H; Liu H
    J Biopharm Stat; 2016; 26(2):339-51. PubMed ID: 25629564
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Retrospective robustness of the continual reassessment method.
    O'Quigley J; Zohar S
    J Biopharm Stat; 2010 Sep; 20(5):1013-25. PubMed ID: 20721788
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative review of novel model-assisted designs for phase I clinical trials.
    Zhou H; Murray TA; Pan H; Yuan Y
    Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Continual reassessment method with multiple toxicity constraints.
    Lee SM; Cheng B; Cheung YK
    Biostatistics; 2011 Apr; 12(2):386-98. PubMed ID: 20876664
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The continual reassessment method for dose-finding studies: a tutorial.
    Garrett-Mayer E
    Clin Trials; 2006; 3(1):57-71. PubMed ID: 16539090
    [TBL] [Abstract][Full Text] [Related]  

  • 55. pocrm: an R-package for phase I trials of combinations of agents.
    Wages NA; Varhegyi N
    Comput Methods Programs Biomed; 2013 Oct; 112(1):211-8. PubMed ID: 23871691
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading.
    Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
    Stat Med; 2011 Jul; 30(17):2070-80. PubMed ID: 21344472
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies.
    Zohar S; Chevret S
    Stat Med; 2001 Oct; 20(19):2827-43. PubMed ID: 11568943
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Extending the Continual Reassessment Method to accommodate step-up dosing in Phase I trials.
    Braun TM; Mercier F
    Stat Med; 2022 Sep; 41(20):3975-3990. PubMed ID: 35662077
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CRM and partial order CRM with adaptive rescaling for dose-finding in immunotherapy trials with a continuous outcome.
    Saha PT; Fine JP; Ivanova A
    Stat Med; 2023 Jun; 42(14):2409-2419. PubMed ID: 37012897
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.
    Yuan Y; Lin R; Li D; Nie L; Warren KE
    Clin Cancer Res; 2018 Oct; 24(20):4921-4930. PubMed ID: 29769209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.